Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast...
17 KB (1,479 words) - 03:57, 22 January 2024
Quinazoline (section Lapatinib)
drug lapatinib was approved by the U.S. FDA to treat advanced-stage or metastatic breast cancer in combination with Roche's capecitabine. Lapatinib eliminates...
14 KB (1,240 words) - 15:17, 30 October 2023
8 months (30.9 months vs. 25.1 months) compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. Food and Drug Administration...
29 KB (2,699 words) - 00:43, 10 February 2024
while attempting to determine the toxicity and effectiveness of the drug. Lapatinib, FDA approved for treatment in conjunction with chemotherapy or hormone...
9 KB (1,081 words) - 04:46, 16 June 2022
vulnerability to oxytosis/ferroptosis via a combination of siramesine and lapatinib. These cells also exhibited an autophagic cycle independent of ferroptotic...
23 KB (2,568 words) - 00:30, 6 December 2023
this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bortezomib (Velcade) is an apoptosis-inducing...
20 KB (2,197 words) - 05:50, 29 November 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
68 KB (5,996 words) - 02:41, 17 July 2024
Lantidra Lantrisul Lantus (Sanofi-Aventis) lapaquistat acetate (USAN) lapatinib ditosylate (USAN) lapirium chloride (INN) laprafylline (INN) lapuleucel-T...
4 KB (278 words) - 08:25, 25 December 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
31 KB (3,413 words) - 23:30, 21 June 2024
antibody margetuximab can also prolong survival, as can HER2 inhibitors lapatinib, neratinib, or tucatinib. Certain therapies are targeted at those whose...
129 KB (14,628 words) - 14:31, 8 July 2024
main products are Antineoplastic medicines, which include: Sunitinib Lapatinib Nilotinib Dasatinib Gefitinib Erlotinib Imatinib Canertinib It also produces...
3 KB (192 words) - 23:25, 5 November 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
150 KB (15,741 words) - 10:52, 27 June 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
10 KB (579 words) - 06:46, 26 June 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
63 KB (7,427 words) - 14:51, 9 July 2024
Clinical trials are in progress for other drugs such as everolimus, lapatinib and mifepristone. Common aspirin has been studied as a low-risk therapeutic...
59 KB (6,715 words) - 09:10, 18 July 2024
1) SPOCK2 (Testican 2) SPOCK3 (Testican 3) Testican-1 plays a role in lapatinib resistance, which is a drug used to treat HER2-positive gastric cancer...
2 KB (239 words) - 07:09, 17 November 2023
to develop new therapeutic strategies. HER2 kinase inhibitors, such as lapatinib, have also demonstrated clinical efficacy in HER2 overexpressing breast...
18 KB (2,105 words) - 17:15, 1 December 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
42 KB (3,935 words) - 04:01, 30 April 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
17 KB (1,489 words) - 05:47, 7 April 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
34 KB (3,021 words) - 04:42, 11 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
10 KB (1,131 words) - 19:14, 31 March 2024
approved anti-HER2 therapeutics are also tyrosine kinase inhibitors (Lapatinib, Neratinib, and Tucatinib) and antibody-drug conjugates (ado-trastuzumab...
43 KB (4,651 words) - 05:18, 13 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
15 KB (844 words) - 18:08, 21 March 2024
Huang, Zhen-cong; Chen, Yi-fan; Wang, Xiao-kun; Fu, Li-wu (2014-09-08). "Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug...
66 KB (8,077 words) - 10:16, 9 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
121 KB (13,799 words) - 06:42, 1 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
13 KB (1,177 words) - 16:45, 16 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
5 KB (412 words) - 23:17, 19 June 2023
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
92 KB (8,667 words) - 03:16, 15 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
24 KB (1,700 words) - 04:21, 2 July 2024
inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
25 KB (2,086 words) - 02:24, 16 July 2024